On May 2, 2017, TheraCell, Inc. announced a new patent for their “enhanced cancellous demineralized bone (ECS)” technology. Issued by the United States Patent and Trademark Office, patent number 9,636,436 is helping to expand TheraCell’s vast intellectual property portfolio. The patent, titled “Compositions of and Methods for Cancellous Bone Technology,” is referred to as “a novel approach that has tremendous potential in a range of surgical bone grafting applications” according to TheraCell Chief Scientific Officer Nelson Scarborough, Ph.D.
New Bone Tech From TheraCell
1 min read Premium comments
Secondary
Demineralized bone matrix powder is a common bone void filler in a number of surgical procedures. There are a number of demineralized cancellous sponge items heavily represented in the allograft industry. Cancellous, or “spongy” bone, in the human body boasts a fantastic osteoconductive environment—but often has little osteoconductive properties. TheraCell’s improved technology offers a product that blends the osteoconductivity of demineralized cancellous bone with demineralized cortical bone powder. The result? Better performance.
A Bare-Bones Company
The product comes with “minimal manipulation” and comes on the heels of TheraCell’s other recent patent for Demineralized Bone Fiber (DBF) as well as oxygenation technologies. Company CEO Bradley Patt, Ph.D., says there’s also great potential for synergy when planning for future orthobiologic products.
TheraCell isn’t even a decade old, but has established itself as an osteo-tech leader. Founded to maximize the potential of technology originally developed at Hebrew University by Dan Gazit, Ph.D., D.M.D., the company is now led by a team of spine surgeons. Find out more about TheraCell’s products and innovations at their website.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.